Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

SOC OS for HER2 mBC at 1, 2, and 5 years is 86.6, 63.2, and 23.4% respectively. See Table 2 of Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review. The review is from 2010 but Standard of Care is Standard of Care

http://ascopubs.org/doi/full/10.1200/jco.2008.19.9844

So I was previously thinking, incorrectly, and without ever looking up the data, that metastatic cancer survival is short as is the case in many cancers. So I was lumping mBC in that same timeframe. Boy, that is wrong. As you can see from the OS rates mBC is much better than that. So it is with much greater interest, and anticipation, that I am awaiting the Late Breaking Abstract or more precisely, a Proffered Paper (i.e. Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.) at ESMO 2017 in early September, Geez, that’s just 5 or so weeks away. Note the Korean mBC study closed recruitment in Feb 2016 so we will have 12 month data solidly in hand and 24 month data for a majority of the patients. Ok, I am officially in the “looking forward to results” camp.